Glenmark launches generic formulation for Glaucoma in United States – Healthcare News

Glenmark Pharmaceuticals Inc., USA on Wednesday announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). According to the company’s statement, Glenmark’s Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz, Inc.

According to IQVIA TM sales data for the 12-month period ending September 2024, the Travatan Z Ophthalmic Solution USP, 0.004% market 3 achieved annual sales of approximately $66.2 million.

“We are excited to announce the launch of Travoprost Ophthalmic Solution USP, 0.004%, growing our portfolio of prescription ophthalmic products. This addition highlights our commitment to meeting market needs and providing high-quality solutions for our customers,” Jim Brown, Senior Vice President, Sales & Marketing said.

Glenmark’s current portfolio consists of 200 products authorized for distribution in the U.S. marketplace and 51 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.